Lijun International Pharmaceutical (02005) said its profit attributable to equity holders for the six months ended 30 June 2014 rose 32.2% year-on-year to HK$301 million.
Its basic and diluted earnings per share were HK10.26 cents and HK10.22 cents.
The revenue was HK$1,527 million, an increase of 8.3% from a year earlier.
The increase in profit was mainly attributable to the rapid and efficient development of intravenous infusion solution business. Shijiazhuang No. 4 Pharma materialized a net profit of HK$275 million, representing over 90% of the Group's overall net profit.
The proposed interim and special dividend are HK3 cents and HK3 cents per share.
28/08/2014 14:05
Lijun Int'l (02005) 1H net up 32% to HK$301m; div HK6 cts
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
